Previous 10 | Next 10 |
Investing in companies with superior growth rates can produce outstanding returns over the long term. A stock is essentially a share in the ownership of a business, and the price of the stock will follow the value of the business over time. When the business is growing rapidly and ideally ac...
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present new preclinical data on the anti-tumor activity of SY-5609, its highly selective and potent oral cyclin-dependent kinase 7 (CDK7) inhibitor,...
Syros Pharmaceuticals, Inc. (SYRS) Q1 2020 Earnings Conference Call May 07, 2020, 08:30 ET Company Participants Naomi Aoki - VP, Corporate Communications & IR Nancy Simonian - President, CEO & Director Joseph Ferra - CFO David Roth - Chief Medical Officer Conference ...
Image source: The Motley Fool. Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) Q1 2020 Earnings Call May 07, 2020 , 8:30 a.m. ET Operator Continue reading
The following slide deck was published by Syros Pharmaceuticals, Inc. in conjunction with their 2020 Q1 earnings Read more ...
Syros Pharmaceuticals (NASDAQ: SYRS ): Q1 GAAP EPS of -$0.39 beats by $0.03 . More news on: Syros Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Completed Enrollment in Phase 2 Trial Cohort Evaluating SY-1425 in RARA-Positive Relapsed or Refractory AML Patients On Track for 2020 Milestones, Including Clinical Data Readouts for SY-1425 and SY-5609 Well-Funded with Cash Runway into 2022 Management to Host Conference Ca...
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, May 7, 2020 to report its first quarter 2020 financial results and provide a co...
Introduction Syros ( SYRS ) is a biopharmaceutical company focused on developing treatments for cancer and diseases resulting from mutations of a single gene, also known as monogenic diseases. Its leading drug is SY-1425, a selective retinoic acid receptor alpha agonist, or RARα ago...
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, March 5, 2020 to report its fourth quarter and full year 2019 financial results...
News, Short Squeeze, Breakout and More Instantly...
Syros Pharmaceuticals Inc. Company Name:
SYRS Stock Symbol:
NASDAQ Market:
Syros Pharmaceuticals Inc. Website:
-- Pivotal Complete Response (CR) Data from SELECT-MDS-1 Phase 3 Trial Expected by Mid-4Q24 -- -- Additional Data from SELECT-AML-1 Phase 2 Trial Expected in September 2024-- -- Management to Host Conference Call at 8:30 AM ET Today -- Syros Pharmaceuticals (NA...
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, July 31, 2024 to report its s...
2024-07-19 10:10:00 ET July 19, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech, Cleantech Sectors. The newest biotech companies are involved in blood disorder treat...